drugset / Trial / NCT01686217

A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K

NCT01686217

Phase 1 Completed 30 enrolled Astellas Pharma Global Development, Inc.
RandomizedParallel-groupOpen-label

Summary

The purpose of this study is to compare the pharmacokinetics (PK) profiles of three different strengths of ASP015K extended release formulation and an immediate release formulation and to evaluate food effect on extended release strengths in healthy volunteers.

Timeline

Start
2012-06
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject peficitinib Small molecule Oral

Indications

No indication recorded.